150 related articles for article (PubMed ID: 28881312)
1. LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.
Matsumoto J; Kiesel BF; Parise RA; Guo J; Taylor S; Huang M; Eiseman JL; Ivy SP; Kunos C; Chu E; Beumer JH
J Pharm Biomed Anal; 2017 Nov; 146():154-160. PubMed ID: 28881312
[TBL] [Abstract][Full Text] [Related]
2. Determination of triapine, a ribonucleotide reductase inhibitor, in human plasma by liquid chromatography tandem mass spectrometry.
Feng Y; Kunos CA; Xu Y
Biomed Chromatogr; 2015 Sep; 29(9):1380-7. PubMed ID: 25677991
[TBL] [Abstract][Full Text] [Related]
3. LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma.
Kiesel BF; Parise RA; Wong A; Keyvanjah K; Jacobs S; Beumer JH
J Pharm Biomed Anal; 2017 Feb; 134():130-136. PubMed ID: 27907855
[TBL] [Abstract][Full Text] [Related]
4. LC-MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma.
Kiesel BF; Scemama J; Parise RA; Villaruz L; Iffland A; Doyle A; Ivy P; Chu E; Bakkenist CJ; Beumer JH
J Pharm Biomed Anal; 2017 Nov; 146():244-250. PubMed ID: 28888173
[TBL] [Abstract][Full Text] [Related]
5. LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma.
Holleran JL; Eiseman JL; Parise RA; Kummar S; Beumer JH
J Pharm Biomed Anal; 2016 Sep; 129():359-366. PubMed ID: 27454087
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
7. LC-MS/MS assay for the simultaneous quantitation of the ATM inhibitor AZ31 and the ATR inhibitor AZD6738 in mouse plasma.
Kiesel BF; Shogan JC; Rachid M; Parise RA; Vendetti FP; Bakkenist CJ; Beumer JH
J Pharm Biomed Anal; 2017 May; 138():158-165. PubMed ID: 28213176
[TBL] [Abstract][Full Text] [Related]
8. Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study.
Popović-Bijelić A; Kowol CR; Lind ME; Luo J; Himo F; Enyedy EA; Arion VB; Gräslund A
J Inorg Biochem; 2011 Nov; 105(11):1422-31. PubMed ID: 21955844
[TBL] [Abstract][Full Text] [Related]
9. Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
Parise RA; Egorin MJ; Eiseman JL; Joseph E; Covey JM; Beumer JH
Rapid Commun Mass Spectrom; 2007; 21(13):1991-7. PubMed ID: 17526067
[TBL] [Abstract][Full Text] [Related]
10. A validated enantioselective LC-MS/MS assay for quantification of a major chiral metabolite of an achiral 11-β-hydroxysteroid-dehydrogenase 1 inhibitor in human plasma: Application to a clinical pharmacokinetic study.
Furlong MT; Ji QC; Iacono L; Dang O; Noren M; Bruce J; Aubry AF; Arnold ME
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1022():167-172. PubMed ID: 27100678
[TBL] [Abstract][Full Text] [Related]
11. LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.
Kiesel BF; Parise RA; Tjørnelund J; Christensen MK; Loza E; Tawbi H; Chu E; Kummar S; Beumer JH
J Pharm Biomed Anal; 2013; 81-82():89-98. PubMed ID: 23644904
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.
Kunos CA; Chu E; Beumer JH; Sznol M; Ivy SP
Cancer Chemother Pharmacol; 2017 Jan; 79(1):201-207. PubMed ID: 27878356
[TBL] [Abstract][Full Text] [Related]
13. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of an LC-MS/MS method for the determination of a novel thienoquinolin urea transporter inhibitor PU-48 in rat plasma and its application to a pharmacokinetic study.
Zhang ZY; Wang X; Liu D; Zhang H; Zhang Q; Lu YY; Li P; Lou YQ; Yang BX; Lu C; Lou YX; Zhang GL
Biomed Chromatogr; 2018 Apr; 32(4):. PubMed ID: 29193233
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).
Barker CA; Burgan WE; Carter DJ; Cerna D; Gius D; Hollingshead MG; Camphausen K; Tofilon PJ
Clin Cancer Res; 2006 May; 12(9):2912-8. PubMed ID: 16675588
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a LC-MS/MS assay for quantification of cisplatin in rat plasma and urine.
Shaik AN; Altomare DA; Lesko LJ; Trame MN
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Mar; 1046():243-249. PubMed ID: 28162967
[TBL] [Abstract][Full Text] [Related]
17. An LC-MS/MS method for the quantitation of cabozantinib in rat plasma: application to a pharmacokinetic study.
Su Q; Li J; Ji X; Li J; Zhou T; Lu W; Li L
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Mar; 985():119-23. PubMed ID: 25678398
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry.
Appels NM; van Maanen MJ; Rosing H; Schellens JH; Beijnen JH
Rapid Commun Mass Spectrom; 2005; 19(15):2187-92. PubMed ID: 15996016
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of curcumin diethyl disuccinate and its active metabolite curcumin in rat plasma by LC-MS/MS: Application of esterase inhibitors in the stabilization of an ester-containing prodrug.
Ratnatilaka Na Bhuket P; Niwattisaiwong N; Limpikirati P; Khemawoot P; Towiwat P; Ongpipattanakul B; Rojsitthisak P
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1033-1034():301-310. PubMed ID: 27595650
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a bioanalytical method for the simultaneous determination of heroin, its main metabolites, naloxone and naltrexone by LC-MS/MS in human plasma samples: Application to a clinical trial of oral administration of a heroin/naloxone formulation.
Moreno-Vicente R; Fernández-Nieva Z; Navarro A; Gascón-Crespí I; Farré-Albaladejo M; Igartua M; Hernández RM; Pedraz JL
J Pharm Biomed Anal; 2015 Oct; 114():105-12. PubMed ID: 26037158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
